GlassScriptPhysician profile
Janet E Kercher
NPI 1598161010
$1,578.29
in general payments reported to CMS, 2019-2025
21 companies · $343 in 2025
The $343 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $428 · 2022: $245 · 2023: $308 · 2024: $255 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $905.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $293.23 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $202.76 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $183.18 | 2021-2025 | Airsupra, Breztri |
| Astellas Pharma US INC | $163.90 | 2021-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $91.54 | 2021-2023 | Leqvio |
| Abbott Laboratories | $89.39 | 2021-2024 | Freestyle Libre 3 |
| Dexcom, INC. | $66.28 | 2021-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $62.16 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.04 | 2021-2025 | Jardiance |
| Abbvie INC. | $54.54 | 2021 | |
| Exact Sciences Corporation | $46.22 | 2023-2025 | Cologuard Collection Kit |
| Amneal Pharmaceuticals LLC | $34.49 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $33.60 | 2021 | |
| Insulet Corporation | $33.50 | 2022 | |
| Sanofi-Aventis U.S. LLC | $31.36 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $28.58 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.10 | 2021-2025 | |
| Amgen INC. | $28.07 | 2021-2023 | Repatha |
| Biohaven Pharmaceuticals, INC. | $22.86 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.16 | 2022 | |
| Merck Sharp & Dohme LLC | $14.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Kercher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.